Search for: "AVENTIS PHARMACEUTICALS, INC.," Results 181 - 200 of 219
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
18 Feb 2011, 11:47 am by Sheppard Mullin
The defendants in both sets of actions were Sanofi Aventis and Sanofi-Synthelabo, Inc., Bristol-Myers Squibb Company and Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership (collectively “Sanofi”) and Apotex Corporation (“Apotex”). [read post]
10 Oct 2016, 2:59 pm by Michael Grossman
Taxotere: The Case Against a Chemo Drug Taxotere, the marketed brand name of the drug docetaxel, is a taxane-class drug manufactured by Sanofi-Aventis Pharmaceutical. [read post]
8 Oct 2008, 11:50 am
Aventis Pasteur, Inc., 2008 WL 4144386 (C.P. [read post]
9 Aug 2008, 1:50 am
: (Techdirt), Microsoft Research launches new tools for knowledge sharing: (creativecommons.org), Yet another star singer, Duffy, doesn’t mind file-sharing: (Techdirt)   Events 20 August – Bill Patry speaking on copyright – Melbourne: (Patry Copyright Blog), (LawFont.com), 21 August – Bill Patry speaking on copyright – Canberra: (Patry Copyright Blog), (LawFont.com), 22 August – Bill Patry speaking on copyright – Sydney:… [read post]
2 Aug 2008, 12:54 am
, (Daily Dose of IP), 20 August – Bill Patry Copyright Blog speaking on copyright – Melbourne: (Patry Copyright Blog), (LawFont.com), 21 August – Bill Patry Copyright Blog speaking on copyright – Canberra: (Patry Copyright Blog), (LawFont.com), 22 August – Bill Patry Copyright Blog speaking on copyright – Sydney: (Patry Copyright Blog), (LawFont.com), 26 August: WIPO symposium on IP and multilateral agreements – Geneva: (IPKat),… [read post]
13 Jun 2008, 3:40 am
: (Patent Docs), Generic drug developers will continue to take advantage of global demand for lower-priced drugs, with Teva poised to maintain lead position says Goldman Sachs analyst: (GenericsWeb), Daiichi Sankyo takeover of Ranbaxy: (Profitability through Simplicity), (Spicy IP), (GenericsWeb), Canada: Generics to penetrate 26% pharma market in Canada says RNCOS research: (GenericsWeb), Canada: Generic drug makers spreading misinformation about patent regulation amendments to dodge real story:… [read post]
27 Aug 2010, 2:41 pm by Bexis
Ortho Pharmaceutical Corp., 209 Cal. [read post]
16 Aug 2008, 2:43 am
– discussion of Washington Post article on Ismed’s efforts to promote follow-on biologics approval pathway: (Patent Baristas), (Patent Docs), US: Congressional fact-finding on follow-on biologics: (Patent Docs), US: David v Monsanto: Biotechnology patent ‘exhaustion’ after Quanta, Supreme Court petition: (Hal Wegner), US: Ulysses Pharmaceuticals announces issuance of patent for novel class of ant [read post]
8 Feb 2008, 7:00 pm
– Facebook’s contractual rights to users’ photos problematic: (Spicy IP)PharmaEuropean Commission probes pharmaceutical sector: (Philip Brooks),WHO Board sets course on IP, avian flu, tighter publication policy: (Intellectual Property Watch),India: The Competition Act, patents and over hyped drugs: (Part I - Spicy IP), (Part II – Spicy IP), (Part III – Spicy IP),Ignoring not the solution … [read post]
21 Oct 2011, 2:00 am by Stefanie Levine
Patent No. 6,794,410 entitled USE OF (Z) -2-CYANO-3-HYDROXY- BUT-2-ENOIC ACID-(4-TRIFLUOROMETHYLPHENYL) -AMIDE FOR TREATING MULTIPLE SCLEROSIS and owned by Aventis Pharmaceuticals. [read post]
21 Oct 2011, 2:00 am by Stefanie Levine
Patent No. 6,794,410 entitled USE OF (Z) -2-CYANO-3-HYDROXY- BUT-2-ENOIC ACID-(4-TRIFLUOROMETHYLPHENYL) -AMIDE FOR TREATING MULTIPLE SCLEROSIS and owned by Aventis Pharmaceuticals. [read post]
15 May 2011, 2:54 pm by FDABlog HPM
LLC, Watson Pharmaceuticals, Inc., and Synthon Holding B.V. notifying them that the Bureau believes the companies violated federal law by failing to inform antitrust authorities about patent agreements involving Sanofi’s insomnia drug AMBIEN CR (zolpidem tartrate) Tablets, but that instead of recommending that the FTC take enforcement action, it would issue advisory letters. [read post]
26 May 2015, 7:42 am
  Claims such as in Mills, which are at loggerheads with FDA criteria for drug development, are precisely those with the most potential for making pharmaceutical manufacturers into “sitting ducks” for litigation, in this instance litigation based on extraneous genetic factors.It may well be that the coming (and to some extent existing) revolution in genetically individualized medical therapy will require changes in how drugs are evaluated, labeled, etc., but this is a… [read post]
15 Mar 2008, 7:00 am
India: Gene silencing: (Spicy IP), India: US Patent reform implications for Indian Pharma: (Spicy IP), India: Generic pharmaceutical industry in the spotlight: (International Law Office), India: Supreme Court refuses to stay a Gujarat High Court decision restraining Ranbaxy from airing its controversial ads directed against Paras Pharma's 'Moov' brand: (Spicy IP),India: Patents on ARV drugs could increase costs: (Generic Pharmaceuticals & IP),US: Survey… [read post]
28 Apr 2011, 3:18 pm by Bexis
By now Restatement (Second) of Torts §402A (1965) is so old as to be thought of as somewhat antediluvian. [read post]